IDO1 and glioblastoma: Five clinical trials are currently ongoing for patients with glioblastoma using the pharmacological inhibition of IDO-1 in combination with TMZ and/or anti-PD-1 antibody (www.clinicaltrials.gov, accessed on 29 March 2021).